Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by PTBaileyon Oct 13, 2021 11:44am
132 Views
Post# 34001211

RE:Salz Shares !!!

RE:Salz Shares !!!
HighSkies2019 wrote: Not sure if I am missing any part of the equation... I see concerns on ownership and shares and wanted to chk for myself ..Bailey or anyone is this correct pls and thx...Just looking over the LOI for PAH lisence ...26 mil pre split equals 1.3 mil post split (2600000020)... 20% of 35.41 mil equals 7.082 (354100000.20).... right now on sedi it shows balance of 5395500 shares in Salz account ... this amount I used as the latest date of transaction 10/10/21 far left on sedi date .... so 7.082 mil is 20% of 35.41 mil minus salz account 5395500 balance .(7082000-5395500= 1686500) ...and we need to give Salz 1.3 mil shares for PAH (1686500-1300000) were still under 20% to Salz ownership... I pulled this from nr april 2021...... Upon execution of the definitive PAH License Agreement, Claritas will issue 26 million shares of Claritas common stock to Salzman Group, Inc. Provided, however, that Claritas will not issue any common shares to Salzman Group, Inc. unless Salzman Group, Inc. and all affiliates certify that the issuance of such common shares will not cause Salzman Group, Inc. and its affiliates to beneficially own in excess of 19.99% of the Companys outstanding shares of common stock;Claritas will pay cash license fees of USD $12,300 to Salzman Group Pty. Ltd. and USD $287,70 to Salzman Group Ltd. within 90 days of the execution of the definitive PAH License Agreement;


No sure on all the math but I believe you are correct. This is from Amazigh, who is well informed on this stock, from another site.

"That is my understanding too. Salzmangroup needs to be paid so the PAH license is owned by CLAS. To allow that to happen it seems Salzman is prepared to sell some of his shares, so CLAS can pay (in part) in shares for the PAH license. We probably will get this week a news release stating the Obsidian deal is accepted by TSXV, and maybe also the closing of the PAH license deal with the Salzmangroup. If I am correct, Salzman will then have again almost 20% of CLAS shares."
<< Previous
Bullboard Posts
Next >>